DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Brahmer J. et al.
Health-related Quality of Life for Pembrolizumab vs. Chemotherapy in advanced NSCLC with PD-L1 TPS ≥50%; Data from KEYNOTE-024.
abstr. PL04a.01
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.